Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

From HARMONi-2 Vs Keytruda In NSCLC

 
• By Dexter Jie Yan
  
Investors' expectations are high that Akeso and Summit Therapeutics' ivonescimab could eventually best Merck's Keytruda in overall survival for the first-line treatment of PD-L1-positive non-small cell lung cancer. (Shutterstock)

More from China

More from Clinical Trials